orvepitant

DRUG6 trials

Sponsors

GlaxoSmithKline, Nerre Therapeutics Ltd.

Conditions

Atopic DermatitisDepressive DisorderDepressive Disorder, MajorPharmacokinetic Study in Healthy Male VolunteersPost-Traumatic Stress DisorderPruritus

Phase 1

Food and Relative Bioavailability Study

CompletedNCT00843011

GlaxoSmithKlineDepressive Disorder

Start: 2008-08-28End: 2008-10-23Updated: 2017-07-21

A Pharmacokinetic Study of the Effect of Itraconazole Exposure to Orvepitant in Healthy Volunteers

CompletedNCT03535662

Nerre Therapeutics Ltd.Pharmacokinetic Study in Healthy Male Volunteers

Start: 2018-06-08End: 2018-08-09Updated: 2018-10-11

Phase 2

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

TerminatedNCT00880399

GlaxoSmithKlineDepressive Disorder, Major

Start: 2009-03-01End: 2010-06-16Updated: 2017-09-12

A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

TerminatedNCT00880048

GlaxoSmithKlineDepressive Disorder

Start: 2009-03-11End: 2010-06-21Updated: 2017-10-13

Orvepitant (GW823296) in Adult Post Traumatic Stress Disorder

CompletedNCT01000493

GlaxoSmithKlinePost-Traumatic Stress Disorder

Start: 2009-11-02End: 2010-06-28Updated: 2017-09-01

A Study of the Efficacy and Safety of Orvepitant in Subjects With Pruritus Associated With Atopic Dermatitis

WithdrawnNCT03464526

Nerre Therapeutics Ltd.Atopic Dermatitis, Pruritus

Start: 2018-05-31End: 2019-10-31Updated: 2018-05-15